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Immune thrombocytopenia (ITP) is an autoimmune 
disorder characterised by immunological destruction 
of platelets (primarily due to the production of 
platelet-reactive autoantibodies), along with an 
inability to compensate by increasing production 
of platelets as a result of immune-mediated megakaryocyte damage 
and dysfunction.[1] In ITP a platelet count of >30 × 109/L is 
generally the goal of treatment, but the decision to treat should be 
based on the patient’s risk of bleeding, side-effects of medication 
and patient preference.[2] First-line treatment for ITP is with oral 
glucocorticoids. Splenectomy has traditionally been employed as 
second-line treatment, but newer drugs such as rituximab and 
thrombopoeitin (TPO) agonists have brought the role of surgery 
into question.
Thrombocytopenia is a common problem in HIV owing to 
cross-reactivity of antibodies to HIV with glycoprotein GPIIb and/
or GPIIIa on the platelet surface or talin within the platelet cyto-
skeleton.[3,4] Treatment of HIV-associated ITP is with antiretroviral 
therapy (ART). The use of glucocorticoids is common but is based 
purely on expert opinion, since there are no trials of glucocorticoids 
in HIV-associated ITP. Zidovudine was the first antiretroviral to 
show response in treating HIV-related thrombocytopenia. However, 
owing to the risk of generating resistance with monotherapy, com-
bination antiretroviral therapy (cART) is preferred (not necessar-
ily including zidovudine) and has been shown to be as effective.[5] 
Splenectomy for ITP in HIV has been reported mainly in the pre-
ART era and its role in HIV-associated ITP in the current era of ART 
needs to be studied further.[6]
Splenectomy has been reported to have a complete response 
(CR) rate of 85%, but up to 25% of patients relapse during a 
5-year period.[7-9] The most concerning late complication of 
splenectomy is overwhelming post-splenectomy infection, the 
risk of which is estimated to be 0.23 - 0.42% per year, with a 
lifetime risk of 5%.[10]
Rituximab is a monoclonal antibody directed against epitopes in B 
lymphocytes and has been studied in treatment-resistant ITP, but has 
shown poorer outcomes compared with splenectomy, with a 4.4-fold 
lower probability of CR at 1 year and a response rate of only 20% at 
5 years.[11,12] In a systematic review of 306 ITP patients treated with 
rituximab, 3.7% experienced severe or life-threatening events and 
2.9% (9 patients) died.[13]
More recently, recognising that platelet underproduction and 
megakaryocyte dysfunction play a substantial role in the patho-
physiology of ITP, TPO receptor agonists such as romiplostim and 
eltrombopag have become available. They are costly, and as they 
have little influence on the immune destructive process they need 
to be taken indefinitely. These TPO agonists have nevertheless 
been associated with responses (platelet count >50 × 109/L at 6 - 8 
weeks) in up to 92% of patients, continuing as long as treatment is 
maintained.[14] TPO agonists are well tolerated, with a 5-year follow-
up study for romiplostim reporting an 8% rate for serious adverse 
events and 5% mortality.[14] Rituximab and TPO agonists have not yet 
been studied systematically in HIV-associated ITP.
Considering these non-invasive treatment options, the role of 
splenectomy continues to be debated. We therefore undertook to 
investigate response rates to splenectomy in patients with ITP, some 
of whom were HIV-positive and who had been pretreated with 
steroids in an era when cART was available. To our knowledge this is 
the first study reporting outcomes after splenectomy in Africa, in a 
context of high infectivity with HIV.
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Background. New agents are being used as second-line treatment for immune thrombocytopenia (ITP) and have brought into question the 
relevance of splenectomy for steroid-resistant ITP.
Methods. We retrospectively analysed 73 patients who underwent splenectomy for ITP at our institution over an 11-year period. The 
median follow-up period was 25 months; patients with follow-up of <1 month were excluded. The outcomes of splenectomy were compared 
in HIV-positive v. HIV-negative patients.
Results. The rate of complete response was 83%, and response was sustained for at least 1 year or until latest follow-up in 80% of patients. 
Twelve patients were HIV-positive. Splenectomy was laparoscopic in 43 patients (62%) with an overall 16% complication rate. The 90-day 
mortality rate was 1.38%. There was no statistically significant difference in response or complication rate in the HIV-positive patients. 
There was a statistically significant (p=0.017) poorer response to splenectomy in the patients with steroid-resistant ITP.
Conclusion. Splenectomy is effective and safe irrespective of HIV status and remains an appropriate second-line treatment for ITP. Further 
research is needed to corroborate our finding of lower response in patients who are steroid-resistant, as this might be a subgroup of patients 
who may benefit from thrombopoietin agonists as second-line therapy.
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Methods
Patient selection
Seventy-three consecutive patients who 
had undergone splenec tomy for ITP during 
the period 1 January 2001 - 31 December 
2011 were retrospectively identified using 
surgical and histological records. Patients 
with primary ITP as well as patients with 
secondary ITP due to HIV, hepatitis and 
connective tissue disease were included, but 
patients with lymphoproliferative disease 
were excluded. Patients who had platelet 
counts lower than response (<30 × 109/L) 
on high-dose steroids or who relapsed 
after steroid treatment and weaning were 
referred for splenectomy.[2] All patients 
met the diagnostic criteria reported by the 
American Society of Hematology Practice 
Guidelines.[2] This record review was 
approved by the ethics committee of the 
University of Cape Town.
The medical records of these patients were 
analysed for their clinical and laboratory 
data with regard to diagnosis and initial 
management, comorbidities, response to 
treatment, recurrence of thrombocytopenia, 
salvage therapy, operative type of 
splenectomy, follow-up platelet counts and 
complications following splenectomy.
After splenectomy the platelet counts at 1 
month, 6 months, 1 year or at latest follow-
up (up to September 2013) were recorded 
to assess response. All platelet counts were 
checked and if there was any platelet count 
in the follow-up period <100 × 109/L this was 
specifically noted. The correlations between 
HIV status, hepatitis B positivity, antinuclear 
antibody (ANA) positivity (signalling 
connective tissue disease), gender, age and 
the likelihood of a CR after splenectomy 
were analysed.
Definitions
Response to medical treatment
Steroid resistance. Platelet count of >30 × 
109/L never recorded despite treatment with 
prednisone at a minimum dose of 1 mg/kg 
for at least 6 weeks.
Steroid dependence. Platelet count 
dropping to <30 × 109/L within 6 months 
from weaning off steroids.
Response to splenectomy
We used the definitions of response as 
previously described in the literature, with 
the addition of ‘sustained response’ as 
defined.[7] 
CR. Achievement and maintenance of a 
platelet count >100 × 109/L for all measure-
ments 30 days or longer after splenectomy 
and with no additional treatment for ITP, 
except for the tapering of glucocorticoids.
Partial response. A platelet count of 
>30 × 109/L for all measure ments 30 days 
or longer after splenectomy, with or without 
other treatment, excluding patients who 
qualify for CR. All patients who relapsed 
after initially achieving a normal platelet 
count were therefore considered to have a 
partial response.
No response. The platelet count never 
increased to >30 × 109/L for any measurement 
30 days or longer after splenectomy.
Sustained response. A platelet count of 
>100 × 109/L for all measurements for at 
least 1 year or until last follow-up if follow-
up lasted longer than 1 year.
Definition of hepatitis B-positive 
and ANA-positive
Patients were regarded as having chronic 
hepatitis B if the surface antigen was positive 
or if there was a recorded viral load on 
polymerase chain reaction on the National 
Health Laboratory Service system. Over the 
time period of the study, ANA was reported 
as positive if it was above the laboratory 
reference range.
Statistics
Microsoft Excel 2010 (Microsoft Corporation, 
USA) was used for database and data input. 
Statistical analyses were performed using 
STATA statistical software, version 12.0 
(STATA Corporation, USA). Descriptive 
characteristics of the patients were analysed, 
and means (standard deviations) were used for 
normally distributed data and medians plus 
interquartile ranges (IQRs) for non-normally 
distributed data. Survival analysis was based 
on the Kaplan-Meier estimate and the log-
rank test was used for survival comparisons. 
To assess the association between variables 
and CR, the prevalence ratio (PR) was 
calculated (since the prevalence of the ‘CR’ 
was >10% and in this situation odds ratios 
(ORs) overestimate the magnitude of risk) 
and the p-value was calculated by logistic 
regression. Continuous and categorical 
variables were compared using the χ2 test, and 
when the expected frequencies in any cell of 
the contingency tables were <5 Fisher’s exact 
test was used. All p-values were considered 
significant at p<0.05. To compare means, if 
the data were normally distributed (tested 
by doing a Shapiro-Wilk test), a t-test was 
performed; if the data were non-normally 
distributed, a Wilcoxon-Mann-Whitney test 
was performed.
Results
Patient characteristics (Table 1)
The median age at splenectomy was 33 years 
(IQR 22 - 44). There was a female preponder-
ance with a ratio of 3:1; 56 patients (77%) were 
female. Twelve patients were HIV-positive 
(16%); in 15 the HIV status was unknown. 
Of the 36 patients for whom the hepatitis 
B status was known, 5 were positive (14%). 
Two patients were pregnant, and one patient 
underwent splenectomy while pregnant.
Medical treatment prior to 
splenectomy
Of the patients for whom details regarding 
treatment prior to splenectomy were available 
(n=66), 54 (82%) were steroid dependent and 
12 (18%) were steroid resistant. All patients had 
received glucocorticoids at a dose of at least 1 
mg/kg/d, and in 27 patients the dose had been 
2 mg/kg/d. Prior to splenectomy, azathioprine 
was prescribed to 23 patients (33%) (Table 2).
HIV-positive population
Of the HIV-positive patients, 7 were female 
and 5 male and the median age was 36 years 
(IQR 27 - 40). The median CD4 count at 
diagnosis of ITP was 253 cells/µL (IQR 163 - 
458); 7 (58%) patients had counts <300 cells/
µL, 2 had counts >700 cells/µL, and 1 patient 
had a count of 458 cells/µL. The CD4 count 
was unknown in 2 patients.
cART was given to 11 patients prior to 
splenectomy (for ITP regardless of CD4 
Table 1. Patient characteristics at 
diagnosis (N=73)
Variables
Age (yrs), median (range) 33 (16 - 70)
Gender, n (%)
Male 17 (23)
Female 56 (77)
HIV status, n (%)
Positive 12 (16)
Negative 46 (63)
Unknown 15 (21)
Hepatitis B status, n (%)
Positive 5 (7)
Negative 31 (42)
Unknown 37 (51)
ANA, n (%)
Positive 19 (26)
Negative 20 (27)
Unknown 34 (47)
Comorbidities, n (%)
Diabetes 8 (11)
SLE 9 (12)
TB 10 (14)
SLE = systemic lupus erythematosus; TB = tuberculosis.
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count) for a median duration of 12 months 
(range 2 - 60). All patients on cART were on 
a regimen comprising two nucleoside reverse 
transcriptase inhibitors (a combination of two 
of zidovudine, lamivudine and stavudine) 
and a non-nucleoside reverse transcriptase 
inhibitor (either nevirapine or efavirenz). 
Three patients were being treated with cART 
prior to developing ITP and the other 9 patients 
developed ITP and were subsequently put onto 
cART (n=7) or AZT monotherapy (n=2).
Operative information
Of the 69 patients for whom operative 
details were available, 26 patients (38%) 
had their splenectomy by open laparotomy 
and 43 (62%) by laparoscopy, with an 
increasing number of laparoscopic 
procedures performed in the later years. 
The median platelet count at splenectomy 
was 187 × 109/L (IQR 125 - 172). Patients 
were actively treated preoperatively with 
platelet transfusions (n=4), intravenous 
dexamethasone (n=4) and intravenous 
immunoglobulin (n=4) to raise the platelet 
count in the short term.
The median time from presentation 
to splenectomy at our institution was 4.7 
months (IQR 2.6 - 13) (HIV-negative and 
positive). In the HIV-positive population it 
was 3.2 months (IQR  2.1  - 5.9) (p=0.138). 
This short time to splenectomy is explained 
by the fact that many patients were referred 
after initially being managed at a secondary-
level hospital. The time from initial diagnosis 
could not be established in 15 patients.
Median time to discharge was on the 3rd 
postoperative day (IQR 2 - 4 days); for HIV-
positive patients it was day 3 (IQR 2 - 3 days; 
p=0.5). The intraoperative complication 
rate for splenectomy was 10% and included 
conversion to open splenectomy for bleeding 
(n=2), and intra-abdominal adhesions (n=3). 
There was no intraoperative mortality.
There were 11 postoperative complications 
in 10 patients (16% all-cause complication rate). 
The most common postoperative complication 
was infection (Table 3). Two patients developed 
postoperative thrombosis: one patient presen-
ted 8 days after surgery with a pulmonary 
embolism, and the other developed thrombus in 
the mesenteric vein. Both patients had normal 
platelet counts at presentation with thrombosis.
Operative bleeding in two patients 
was associated with surgical difficulties 
(damage to abdominal vessels) and was not 
spontaneous or secondary to usual surgical 
technique; in both, there were no further 
complications after conversion to open 
splenectomy.
There was no statistically significant 
difference in postoperative complications 
according to method of splenectomy. The 
complication rate in the HIV-positive 
patients was non-significantly higher than 
in the HIV-negative patients (18% and 16%, 
respectively; p=0.59).
There was one postoperative death at 10 
weeks post surgery, giving a 90-day mortality 
rate of 1.38%. This patient was HIV-positive, 
had an uncomplicated splenectomy and was 
discharged on day 2 post operation. She 
presented again 10 weeks later in septic 
shock (with an unidentified organism) and 
required inotropic support and dialysis. Her 
platelet count remained <30 × 109/L and 
she died within 24 hours of admission. Of 
note, this patient had received the 23-valent 
pneumococcal vaccine as an inpatient the 
day before her surgery.
Response to splenectomy
Patients were followed up for a median 
period of 25 months from splenectomy 
(IQR  12 - 69). Among the patients for 
whom platelet counts were known for at 
least a month and could be included in 
the analysis (n=65), the CR rate was 83% 
(n=54); 11% (n=7) had a partial response 
and 6% (n=4) no response. Details for up to 
1 year were known for a total of 55 patients, 
revealing that the sustained response rate 
was 80% (n=44). At 1 year there was no 
statistically significant difference between 
HIV-positive and negative patients’ platelet 
counts (p=0.69). The group of patients for 
whom HIV status was unknown had a 90% 
CR that was non-statistically different from 
those with known HIV status (p=0.46).
Eleven patients did not have a CR. Of 
these, 7 had a partial response (the median 
platelet count at 1 year was 113 × 109/L, 
but response was defined as partial owing 
to fluctuation) and 4 had no response to 
splenectomy. All 11 patients were retreated 
with steroids, and 4 were treated with 
azathioprine. Of the 7 patients with a partial 
response, 6 later achieved platelet counts 
of >100 × 109/L and were weaned off all 
therapies.
Predictors of response
For an association between variables and 
CR, a PR was calculated (Table 4). Only one 
variable showed a statistically significant 
poorer response to splenectomy. This was 
steroid-resistant ITP (PR 0.62; p=0.003).
Morbidity and mortality
Seven patients (5 males and 2 females) died 
in the follow-up period. The total patient 
follow-up time was 3 710 months, with a 
mortality rate of 1.89/1 000 patient months 
(confidence interval (CI) 0.90 - 3.96). Six 
patients with recorded deaths were HIV-
negative and one was HIV-positive. There 
was no statistically significant difference 
in mortality rate in the groups by gender 
(p=0.37) or HIV status (for the HIV-positive 
group 1.7 deaths/1 000 patient months and 
for the HIV-negative group 2.4 deaths/1 000 
patient months; p=0.96).
There was a statistically significant dif-
ference in mortality rate (p=0.001) between 
Table 2. Treatments given and response 
type to glucocorticoids (N=66)
n (%)
Response to oral steroids 
Steroid dependent 54 (82)
Steroid resistant 12 (18)
Treatment 
Prednisone 66 (100)
Azathioprine 23 (33)
Polygam 6 (9)
IVI dexamethasone 5 (7)
Plasmapheresis 5 (7)
Cyclophosphamide 2 (3)
Dapsone 1 (1)
Danazol 1 (1)
IVI = intravenous infusion.
Table 3. Operative information
Type of splenectomy (N=69), n (%)
Open laparotomy 26 (38)
Laparoscopic 43 (62)
Intraoperative complications 
(N=60*), n 
Mortality -
 Adhesions (converted to open 
splenectomy)
3
 Bleeding (converted to open 
splenectomy)
2
 Conversion to open  
splenectomy, reason not found
2
Postoperative complications 
(N=60*), n 
Death 1
Intra-abdominal sepsis 5
Wound infection 2
Thrombosis 2
Drip site sepsis 1
 Subacute small-bowel 
obstruction
1
 *Data missing for 9 patients.
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the group that had achieved CR following 
splenectomy (2 deaths; 0.87/1  000 patient 
months) and the group that had not had a 
CR (5 deaths; 13.6 /1 000 patient months) 
(Fig. 1).
Four deaths may have been directly related 
to the splenectomy: 3 were secondary to 
sepsis (being asplenic may have contributed to 
excess mortality risk from sepsis) and 1 from 
a cerebrovascular accident which may have 
been attributable to rebound thrombocytosis 
(this patient’s platelet count was 1 214 × 109/L 
at the time of readmission). All four patients 
were on further immunosuppressive therapy 
(steroids or azathioprine), which may have 
contributed to their increased risk of sepsis. 
One death was related to the underlying 
disease (thrombocytopenia) and one unrelated 
and due to prostate cancer (Table 5). There was 
100% mortality in the non-responders, with all 
four patients with no response to splenectomy 
dying in the follow-up period.
Discussion
In our analysis, CR was seen in 83% and 
was sustained in 80%, which is similar 
to that reported in the literature.[7,8,15] Of 
those who achieved partial response, with 
the addition of glucocorticoids and/or 
azathioprine 86% (n=6) later progressed to 
CR, which was maintained for the duration 
of follow-up. This is in keeping with other 
studies showing that a partial response is 
also consistent with a favourable long-term 
outcome.[7] In our experience, the CR rate to 
splenectomy (platelet count >100 × 109/L) 
and duration of response appear higher than 
that reported for rituximab and similar to 
that of the TPO agonists (with maintenance 
of treatment).[11,14] There was a 100% (n=4) 
mortality rate in the patients who showed no 
response following splenectomy; however, 
only one death was secondary to bleeding. 
Continued immunosuppression is likely to 
have contributed to their overall mortality.
In the HIV-positive patients, the CD4 
count at diagnosis of ITP demonstrated 
the typical bimodal distribution show-
ing ITP early in HIV with CD4 counts 
>700  ×  106/L, and in late disease with CD4 
counts <300  ×  106/L. In our small (n=12) 
HIV-positive cohort the treatment response 
was favourable and outcomes were not sig-
nificantly different from the HIV-negative 
cohort. These obser vations need to be con-
firmed in a larger population, but they are in 
keeping with the only large-scale study look-
ing at splenectomy in HIV-associated ITP, 
where the response rate to splenectomy was 
92% and a favourable long-term (6-month 
response) outcome was seen in 82%.[6] The 
complications, morbidity and mortality asso-
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Fig. 1. Kaplan-Meier survival estimates by CR.
Table 4. Variables and rate of CR with calculated PRs and ORs
Variables N
CR
n (%) PR OR CI  (for OR) p-value
Gender
Male 16 12 (75) 0.88 0.5 0.11 - 2.76 0.44
Female 49  42 (85)
HIV status
Positive 12 9 (75) 0.89 0.58 0.11 - 4.23 0.38
Negative 43 36(84) 
Hepatitis B 
Positive 5 4(80) 1.05 0.78 0.06 - 43.7 0.61
Negative 29 22(76)
ANA
Positive 19 17 (89) 0.95 0.5 0.01 - 10.7 0.52
Negative 18 17(94)
Diabetes
Yes 8 7(88) 1.06 1.4 0.14 - 70.0 0.62
No 54 45(83)
TB
Positive 10 6(60) 0.69 0.21 0.03 - 1.36 0.06
Negative 55 48(87)
Azathioprine 
Yes 23 17(74) 0.82 0.22 0.03 - 1.26 0.06
No 33 30(90)
Steroid resistant 
Yes 11 6(54) 0.62 0.24 0.29 - 0.89 0.017
No 51 46(87)
SLE
Yes 8 6 (75) 0.89 0.59 0.09 - 6.9 0.42
No 55 46(84)
TB = tuberculosis; SLE = systemic lupus erythematosus.
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ciated with splenectomy were not statistically 
different in the HIV-positive compared with 
HIV-negative cohorts. While the complica-
tion rate in our cohort was slightly higher 
than previously reported, this is difficult to 
interpret since other publications did not 
define what they considered to be ‘complica-
tions’, while we included minor complications 
such as drip site sepsis.[2]
We speculate that the unfavourable 
response to splenectomy in patients with 
steroid-resistant disease is possibly due to 
greater megakaryocyte dysfunction, in addi-
tion to increased peripheral consumption. 
If proven, this could be an important find-
ing as it may help to identify patients who 
would benefit from TPO agonists rather 
than pursuing measures that aim to decrease 
peripheral consumption. 
Conclusion
The conclusions from this study are 
encouraging and support the view that because 
of its effectiveness, splenectomy should remain 
the second-line treatment for ITP in most 
patients, including HIV-positive patients. We 
have also identified a patient population with 
a statistically significant poorer outcome to 
splenectomy, and further research is needed 
to distinguish patients whose ITP is primarily 
due to peripheral consumption (the majority 
of patients with ITP), and who would therefore 
be likely to benefit from immunosuppression 
(such as glucocorticoids and splenectomy), 
from those whose ITP reflects megakaryocyte 
dysfunction predominantly and who would 
benefit from TPO agonists. This may be the 
first step towards generating more patient-
specific, and mechanism-driven, treatment 
strategies for the second-line treatment of ITP.
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Table 5. Causes of mortality
Gender Age, years
Months post 
splenectomy Cause of death
Male 24 17 Pneumococcal sepsis
Male 70 6 Prostate cancer*
Female 50 5 CVA (rebound thrombocytosis)
Female 32 2.5 Sepsis (pathogen unknown)
Female 23 68 Sepsis (ruptured appendix)*
Female 26 91 Intracerebral haemorrhage (platelet count <10 × 109/L)
Female 24 52 Unknown*
CVA = cerebrovascular accident.
*Patients with no response to splenectomy.
